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Abstract
GATA2 deficiency syndrome (G2DS) is a rare autosomal dominant genetic disease
predisposing to a range of symptoms, of which myeloid malignancy and im-
munodeficiency including recurrent infections are most common. In the last decade
since it was first reported, there have been over 480 individuals identified carrying a
pathogenic or likely pathogenic germline GATA2 variant with symptoms of G2DS,
with 240 of these confirmed to be familial and 24 de novo. For those that develop
myeloid malignancy (75% of all carriers with G2DS disease symptoms), the median
age of onset is 17 years (range 0–78 years) and myelodysplastic syndrome is the first
diagnosis in 75% of these cases with acute myeloid leukemia in a further 9%. All
variant types appear to predispose to myeloid malignancy and immunodeficiency.
Apart from lymphedema in which haploinsufficiency seems necessary, the muta-
tional requirements of the other less common G2DS phenotypes is still unclear.
These predominantly loss‐of‐function variants impact GATA2 expression and
function in numerous ways including perturbations to DNA binding, protein struc-
ture, protein:protein interactions, and gene transcription, splicing, and expression. In
this review, we provide the first expert‐curated ACMG/AMP classification with
codes of published variants compatible for use in clinical or diagnostic settings.
K E YWORD S
GATA2 deficiency syndrome, germline variants, immunodeficiency, lymphedema, myeloid
malignancy, predisposition
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
© 2021 The Authors. Human Mutation Published by Wiley Periodicals LLC
Claire C. Homan and Parvathy Venugopal contributed equally to this study.
1 | BACKGROUND
GATA2 deficiency syndrome (G2DS) (MIM#s 601626, 614286,
614038, 614172; GATA2 deficiency with susceptibility to MDS/
AML, MONDO:0042982) is a collective of hematological (malignant
and nonmalignant) and nonhematological phenotypes due to germ-
line predisposing variants in the GATA2 gene that act in a partially
penetrant autosomal dominant manner. Symptoms may range from
life‐threatening bone marrow (BM) failure, immunodeficiency, and/or
myeloid malignancy, to no overt phenotype even at old age, although
the latter is less common. Phenotypes that have been reported in-
clude myeloid malignancies (predominantly myelodysplastic syn-
drome [MDS] and acute myeloid leukemia [AML]), lymphedema
(Emberger syndrome), and immune deficiency (DCML deficiency;
combined deficit of DC, monocyte, B and NK lymphoid cells,
MonoMAC; monocytopenia and mycobacterial infection) with asso-
ciated recurrent infections (Dickinson et al., 2011; Donadieu et al.,
2018; Emberger et al., 1979; Hahn et al., 2011; Hsu et al., 2011;
Kazenwadel et al., 2012; Ostergaard et al., 2011; Spinner et al., 2014;
Wlodarski et al., 2016). Other less common phenotypes include
chronic neutropenia (Pasquet et al., 2013), cytopenia/BM failure
(Ganapathi et al., 2015), pulmonary alveolar proteinosis (PAP), sen-
sorineural deafness, neurological features, urogenital malformations
(Donadieu et al., 2018; Spinner et al., 2014), thrombosis, autoimmune
features, rheumatological features, premature labor, and miscarriage
(Donadieu et al., 2018). Affected individuals may experience multiple
phenotypes throughout their lifetime or even at a single time point,
while others may present with only very mild symptoms.
To date, no single underlying common phenotype has been de-
scribed in the majority of G2DS carriers, in contrast to platelet
function disorder or thrombocytopenia in Familial platelet disorder
with predisposition to acute myeloid leukemia (FPD/AML, MON-
DO:0011071) caused by germline pathogenic variants in the RUNX1
gene. Therefore, it is proposed that each G2DS phenotype arises due
to biological or environmental stressors that act on particular cell
types in which reduced functional GATA2 protein is at or near a
threshold level, thereby creating a situation in which GATA2 activity
becomes limiting for normal cellular function. These “stressor events”
may occur during embryogenesis or after birth and their effects ac-
cumulate over time. A mechanism has been proposed for “hemato-
poietic stem cell exhaustion” due to recurrent or persistent infections
resulting in BM failure (Hirabayashi et al., 2017; Hsu et al., 2015).
One might propose similar mechanisms for each of the phenotypes
such as physical, inflammatory, or infectious stresses on lymphatic
vessels during development causing lymphedema (Kazenwadel et al.,
2015) or more stochastic events leading to malformations of the
auditory system or urinary tract. For myeloid malignancies, germline
GATA2 variants may create a microenvironment that is conducive for
the selection and clonal expansion of particular acquired mutations
such as ASXL1, CEBPA, SETBP1, and −7/7q through a process coined
“predestination” where a limited trajectory of disease evolution is
imposed by pre‐existing variants (i.e., germline) or early (i.e., somatic)
mutations (Papaemmanuil et al., 2013). Here we provide a
comprehensive GATA2 variant update of published germline cases
and include unpublished variants from our institution cohort.
1.1 | Ascertainment criteria of GATA2 variants
Familial and de novo germline GATA2 variants were identified and
extracted from peer‐reviewed literature and collated (Table 1 and
Table S1). GATA2 variants are described according to Human Gen-
ome Variation Society nomenclature and annotated to GenBank ac-
cession number NM_032638.5. Variants were classified according to
American College of Medical Genetics and Genomics (ACMG)/As-
sociation for Molecular Pathology (AMP) guidelines (Richards et al.,
2015) with ClinGen Sequence Variant Interpretation recommenda-
tions (AbouTayoun et al., 2018). A total of 160 unique pathogenic or
likely pathogenic GATA2 variants were identified, with an additional
19 describing partial or complete GATA2 gene deletions, resulting in
haploinsufficiency. Phenotype expansion associated with G2DS has
resulted in the duplication of individuals in the literature carrying
germline GATA2 variants, as more clinical and genetic information has
become available. In this review, we have attempted to remove du-
plication by combining genetic and clinical data for these individuals
as extrapolated from the referenced publications. A total of 480 in-
dividuals carrying a germline GATA2 pathogenic or likely pathogenic
variant were identified (Tables 1 and S1, Figures 1 and 2B). The
available published data confirmed 240 individuals with inherited
variants and 24 individuals carrying de novo variants. For the re-
maining 221 individuals with a G2DS phenotype, insufficient evi-
dence was provided to conclude on the mode of GATA2 variant
acquisition. Classified variants of uncertain significance (VUS) or likely
benign were excluded from analysis, but are provided in Table S2.
GATA2 pathogenic and likely pathogenic variants (ACMG/AMP
classified) are very rarely seen in the general population (only 3 in
total in gnomAD v2.1.1 and 3.0).
1.2 | GATA2 cohort characteristics
In the literature, 359 different families with germline GATA2 variants
have been reported which encompasses 179 different variants (-
Tables 1 and Table S1, Figures 1 and 2A). There is an equal re-
presentation of both males and females presenting with G2DS
phenotypes (1:1.08). In the MDS and MDS/AML population, the
gender ratio was 1:1.04 suggesting no gender bias is associated with
this mechanism of predisposition. This is interesting given a male
bias of 1.8:1 for sporadic adult MDS (Greenberg et al., 2012;
Stauder et al., 2018) and ~6:1 for germline DDX41‐driven MDS
(Lewinsohn et al., 2016; Polprasert et al., 2015; Quesada et al., 2019;
Sébert et al., 2019), and likely reflects the earlier onset of G2DS MDS
associated with mechanistic specificities of disease pathobiology
between different drivers of malignancy. The median age of GATA2‐
driven myeloid malignancy (GDMM) onset is 17 years, with onset
ranging from 0 to 78 years of age, with ~75% of identified GATA2
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carriers developing a malignancy. The median age of onset is mar-
ginally earlier in males as compared to females (17 and 19, respec-
tively). The majority of individuals presented with MDS (56.4%)
followed by MDS/AML (9.12%) and AML (6.9%), with the median age
of onset being 17 years for both MDS and MDS/AML and 20 years
for AML. Four carriers presented with lymphoid malignancy (T‐ or B‐
cell acute lymphoblastic leukemia), although this was rare in com-
parison to the myeloid malignancy (1.1% vs. 98.8%), and may re-
present sporadic cases. Notably, within this small lymphoid
malignancy cohort, two individuals (50%) developed ALL with
monosomy 7 (common in GDMM).
GATA2‐related immunodeficiency is also known as im-
munodeficiency 21 (MIM# 614172). These immunodeficient patients
suffer from recurrent viral (Human papillomavirus leading to warts,
Epstein‐Barr virus), fungal (commonly within the respiratory tract),
and bacterial (most commonly Mycobacterial strains) infections, often
as a result of various cytopenias, predominantly reduced or absent
monocytes, B cells, NK cells, neutrophils, and/or dendritic cells
(Spinner et al., 2014; Tangye et al., 2020). These patients are seen in
primary immunodeficiency cohorts and are often treated with he-
matopoietic stem cell transplantation (HSCT) due to the severity of
immunodeficiency. It is not clear if and to what extent such BM
failure contributes to the development of GDMM (Arts et al., 2019;
Spinner et al., 2014; Stray‐Pedersen et al., 2016).
The range in age of onset and penetrance of disease types, even
within the same family, remains an intriguing mystery, one that if
better understood may lead to beneficial prevention strategies. One
possible answer is that of acquired monoallelic expression due to
epigenetic silencing as a mechanism for further lowering of GATA2
activity levels (Al Seraihi et al., 2018).
1.3 | Type of GATA2 variants
The majority of unique germline pathogenic and likely pathogenic
variants in GATA2 seen in G2DS are loss‐of‐function (LOF) either
through frameshift (40.2%), nonsense (10.1%), splicing (6.7%), or
deletions (15.6%) throughout the gene. Missense variants (25.7%),
mostly in the zinc finger 2 (ZF2) domain, also contribute a large
proportion of the germline GATA2 variants, likely disrupting DNA
binding (Chong et al., 2018; Hahn et al., 2011) or protein–protein
interactions (Bresnick et al., 2020; Chong et al., 2018). The other
important group, accounting for 1.1% G2DS variants, are regulatory,
which affect the GATA2 intron 4 enhancer site and lead to reduced
GATA2 expression in a range of hematopoietic stem and progenitor
cells (Gao et al., 2013; Johnson et al., 2012, 2020; Mehta et al., 2017).
Elegant studies in mice have shown the temporal and cell‐specific
roles of the −77 kb and +9.5 kb (i.e., intron 4) Gata2 enhancers in
development and cell differentiation fates (Bresnick et al., 2020).
Although the repositioning of the equivalent −77 kb GATA2 enhancer
in humans has been shown to be important in t(3;3)(q21;q26) and inv
(3)(q21;q26) in AML in activatingMECOM (Bresnick & Johnson, 2019;
Gröschel et al., 2014; Yamaoka et al., 2020), no germline variants
have been reported in this enhancer to date, possibly a result of this
region not being included in most screening protocols.
Interestingly, there are only a few reports of confirmed missense
germline variants in zinc finger 1 (ZF1). One of these is p.Ala318Thr
(Kurata et al., 2017) which is seen 13 times as a somatic mutation in
COSMIC (v 92) (also p.Ala318Asp/Gly/Val, 25 times) and occurs in a
somatic mutational hotspot (p.Asn317‐Leu321, 95 times) with all in
myeloid malignancies. In vitro transactivation studies demonstrated
partial LOF (Greif et al., 2012; Katsumura et al., 2018). The
p.Ala318Thr case was a 10‐year‐old girl with MDS and she had an
unaffected mother and sister who were both carriers. Of note, a der
(1;7)(q10;p10) was seen in this MDS case, which is a rare transloca-
tion that has been reported multiple times in pediatric/childhood (An
et al., 2019; Wang et al., 2015; Wlodarski et al., 2016) and young
adult MDS (Ganapathi et al., 2015) with pathogenic germline GATA2
variants; this results in chromosome 7q deletion analogous to −7/7q
that is the most common acquired cytogenetic event in GDMM
(Brown et al., 2020). Other ZF1 variants include p.His313Tyr and
p.Leu315Pro, where p.His313Tyr has typical G2DS phenotypes
(Donadieu et al., 2018). Intriguingly, a recent study confirmed a
germline p.Asn317Ser variant (somatic in COSMIC –4 times; p.As-
n317Ile/His, 5 times) in the first reported case of GATA2‐related
primary myelofibrosis, which later progressed to pancytopenia
(Rütsche et al., 2021). It is not clear whether this germline GATA2
variant contributed to this JAK2 positive myeloproliferative neoplasm
and/or if it drove the pancytopenia. Notably, for each of these four
ZF1 variants, there is only one affected individual. Hence, there is a
small but growing number of germline GATA2 ZF1 variants asso-
ciated with G2DS.
The only missense variant outside of ZF1 and the extended ZF2
domain is A286V that is predicted to impact splicing. p.Ala286Val has
been shown to generate a cryptic splice donor site leading to a 16 nt
deletion in RNA studies (Guidugli et al., 2017); hence this variant may
better be described as a frameshift variant. In addition, a seemingly
innocuous synonymous variant (p.Thr117=) has been shown by at
least three groups to strongly alter splicing, generating a predominant
transcript (Kozyra et al., 2020; Wehr et al., 2018) (and our un-
published data) that would result in the variant being more accurately
called p.Val118Glnfs*55 (Fox et al., 2020). Hence, for some variants,
there is an obvious disconnect between their annotation at the DNA
level and their functional effect or impact. With the incorporation of
appropriate bioinformatic tools (e.g., SpliceAI) into variant annotation
pipelines, such cases can be highlighted, but the actual impact on
splicing often requires functional studies for accurate interpretation.
Recurrent variants in the extended ZF2 domain have been re-
ported including p.Thr354Met (53 individuals and 22 families),
p.Arg396Trp (11 individuals and 11 families), p.Arg396Gln (24 in-
dividuals and 16 families), and p.Arg398Trp (22 individuals and 17
families). These variants seem predominantly to be passed on through
familial inheritance although there are two cases of de novo
p.Arg396Gln. Using haplotype mapping, p.Thr354Met was shown to
be both a founder variant (with a common haplotype in an Australian
and USA family) as well as independently derived in another family in
1412 | HOMAN ET AL.
the United States (Hahn et al., 2011). Notably, many of the most
commonly seen germline variants represent potential mutational
“hotspots.” For instance, recurrent GATA2 variants (p.Thr354Met,
p.Arg396Gln/Trp, p.Arg398Gln/Trp, p.Arg362*, p.Arg361His/Cys,
c.1017+572C>T) represent C>T (or G>A) changes at CpG dinucleo-
tides that may be generated by spontaneous or enzymatic deami-
nation of 5‐methylcytosines deposited during normal gene silencing
and regulation. Such mutations (Signature SBS1) are considered part
of the “normal” aging process (Alexandrov et al., 2020), and may
contribute to generation of de novo and “founder” mutations/
variants.
This abundance of Signature SBS1‐like variants in germline
GATA2 differs from another myeloid malignancy predisposition gene,
DDX41, where causal variants predominate within ethnicities or re-
gions (e.g., p.Met1Ile/p.Met1? and p.Asp140Glyfs*2 in Europeans;
p.Val152Gly, p.Ala500Cysfs*9 and p.Tyr259Cys in East Asians) (Choi
et al., 2019; Kim et al., 2020; Qu et al., 2020; Yasuda et al., 2020)
suggesting that these are derived from founder variants that are not
actively selected against in the general population. This is consistent
with the late age of onset of myeloid malignancy for DDX41 pre-
disposition. The often early age of onset of malignancy, im-
munodeficiency, or other phenotypes for G2DS and apparent
anticipation seen in some GATA2 families (Hahn et al., 2011) may
explain a lower level of founder effect and lower predominance of
germline GATA2 variants in sporadic adult MDS or AML cohorts
compared to DDX41 (Kim et al., 2020; Qu et al., 2020; Quesada et al.,
2019; Yasuda et al., 2020).
1.4 | Genotype/phenotype correlations of
germline GATA2 pathogenic and likely pathogenic
variants
Among the reported phenotypes associated with germline GATA2
variants, myeloid malignancy is the most common phenotype (74.3%)
with a median age of onset of 17 years (Figure 2c). This is in stark
contrast with the median age of sporadic disease (MDS, 76 years;
AML, 68 years (Appelbaum et al., 2006; Ma et al., 2007). Im-
munodeficiency was reported in 62% of affected carriers. All variant
types are able to predispose to the three major phenotypes
(Figure 2c).
To date, different types of GATA2 variants have not been linked
strongly to particular subtypes of myeloid malignancy or age of onset
or clinical outcomes. Interestingly, there is a predominance of mye-
loid malignancy with p.Thr354Met (83%; 44/53 cases) and im-
munodeficiency with p.Arg398Trp/Gln variants (85% cases). It
remains to be established if variable clinical presentation is intrinsic to
particular variants or is a consequence of ascertainment bias from
recruitment criteria of various patient cohorts or whether there may
be more prolific local environmental stressors in communities in
which some founder variants are more prevalent.
There have been observations for the requirement of haploinsuffi-
ciency for lymphedema development (Kazenwadel et al., 2012). The
majority of variants reported in lymphedema patients are premature
termination variants (mainly frameshift or nonsense) resulting in hap-
loinsufficiency (Figure 2c). Missense variants associated with lymphedema
are predicted to be LOF and have high REVEL scores (range 0.879–0.989,
median REVEL score 0.954). In vitro DNA binding and transactivation
assays on three of the missense variants found in Emberger syndrome
(p.Arg361Leu, p.Cys373Arg, p.Arg396Gln) demonstrated complete or
almost complete LOF due to markedly diminished DNA binding and
transactivation capacity (Chong et al., 2018; Kazenwadel et al., 2015). In
keeping with haploinsufficiency, of 52 individuals carrying p.Thr354Met
(retains residual GATA2 activity) (Chong et al., 2018; Hahn et al., 2011),
there are no reported cases of lymphedema apart from an isolated case of
vulvar lymphedema (Álvarez‐Chinchilla et al., 2017). The reason that
haploinsufficient GATA2 mutations cause lymphedema is due to a crucial
role for GATA2 in the development and maintenance of lymphatic vessel
valves (Kazenwadel et al., 2015). In the setting of valve dysfunction,
lymph is not efficiently returned to the bloodstream and lymphedema
ensues. Mechanical stimuli including fluid flow and extracellular matrix‐
induced tension, to which endothelial cells are exposed, have been de-
monstrated to regulate GATA2 levels in lymphatic endothelial cells (Frye
et al., 2018, Kazenwadel et al., 2015). Moreover, these distinct mechan-
ical signals induce specific transcriptional outputs; while oscillatory flow
drives lymphatic vessel valve morphogenesis (Kazenwadel et al., 2018),
exposure of cells to soft matrix drives lymphatic vessel sprouting and
migration (Frye et al., 2018). Although hematopoietic transcription factors
including SCL/TAL1 (Janardhan et al., 2017), ERG (Kazenwadel and
Harvey, unpublished), and LMO2 (Coma et al., 2013) are present in
lymphatic endothelial cells, the specific effects of the GATA2 mutations
associated with Emberger syndrome on lymphatic vascular development
suggest that unique transcriptional complexes comprising GATA2 are
present in lymphatic endothelial cells compared to hematopoietic cells
and that these are differentially impacted by distinct GATA2 mutations.
The identification of GATA2 interacting transcriptional components, to-
gether with the signals that regulate their assembly in distinct cell types,
will provide novel insight to the mechanisms by which GATA2 variants
result in the varied phenotypes described in patients with G2DS.
Interestingly, certain GATA2 variants have been shown to display
LOF and gain‐of‐function in different contexts. Though p.Thr354Met
and p.Cys373Arg both disrupt the ZF2 structure in a way that re-
duces or abolishes DNA binding, respectively, they display an in-
creased affinity for a known GATA2‐binding partner protein SPI1
(PU.1) (Chong et al., 2018). This has implications for downstream
targets of both proteins in normal hematopoiesis and may contribute
to leukemogenesis via mechanisms in addition to simple LOF muta-
tions. A similar situation has been reported for certain somatic GATA2
mutations; p.Arg307Trp displays increased ability to skew towards
granulocytic differentiation and induce cell cycle progression
(Katsumura et al., 2018), and p.Leu359Val shows context‐dependent
increased transactivation and DNA binding and the subsequent im-
pact on downstream target genes (Chong et al., 2018; Hahn et al.,
2011; Zhang et al., 2008).
In vitro differentiation studies of certain GATA2 variants showed
increased granulocytic differentiation and a concurrent reduction in
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macrophage differentiation consistent with monocytopenia (Chong
et al., 2018; Cortés‐Lavaud et al., 2015) and a case of noninfectious
granulomatous dermatosis in patients (Polat et al., 2018). Also, pa-
tients with GATA2‐driven MDS display better maintenance of neu-
trophil counts than unselected MDS patients (Collin et al., 2015) and
GATA2 deficient patients display a skewing of B‐cell to T‐cell dif-
ferentiation (Nováková et al., 2016).
1.5 | Somatic mutations associated with
germline GDMM
There are a number of recurrent somatic cytogenetic aberrations
and gene mutations that are seen with germline GDMM. Cyto-
genetically, the most common is monosomy 7, deletion of 7q and
to a lesser extent der(1;7)(q10;p10), all of which effectively results
in a loss of one copy of 7q (at least 49.5% (141/285) cases col-
lectively; note, not all cases reported cytogenetics). Interestingly,
in childhood MDS, these cytogenetic events occur more frequently
than in sporadic cases with monosomy 7 seen in 37% pediatric and
72% adolescent MDS with germline GATA2 variants (Wlodarski
et al., 2016) and der(1;7) is also more prevalent (Kurata et al.,
2017; Wlodarski et al., 2016). Trisomy 8 is the next most common
cytogenetic event occurring in at least 22.8% (65/285) of cases.
Given the relative rarity of germline GATA2 cases and the lack of
routine screening for somatic mutations, estimation of the pre-
valence and range of somatic gene mutations and those that are
mutually exclusive is likely to be only indicative. At the gene level,
ASXL1, NRAS/KRAS, STAG2, and SETBP1 are most commonly seen
somatically mutated in MDS and AML. Interestingly, SF3B1,
U2AF1, NPM1, and FLT3 mutations are uncommon in GATA2‐
driven AML. FLT3 mutations may be rare as the FLT3 ligand is
often elevated in symptomatic G2DS providing elevated stimulus
for FLT3 signaling that may negate selection of spontaneous FLT3
mutations (Dickinson et al., 2011, 2014).
Both monoallelic and biallelic CEBPA somatic mutations are often
associated with somatic GATA2 mutation in sporadic AML (Fasan
et al., 2013; Greif et al., 2012). Although somatic CEBPA mutations
have been reported in germline GDMM (5 cases, Table 1), because of
the past difficulties in sequencing this highly GC‐rich gene, it is un-
clear as to the exact frequency of concurrent CEBPA mutations.
Somatic GATA2 mutations rarely occur in GDMM (i.e., biallelic)
unlike for germline RUNX1, CEBPA, and DDX41‐driven myeloid ma-
lignancies where biallelic mutations are common (Brown et al., 2020;
Cheah et al., 2017). Notably, while germline GATA2 premature ter-
mination mutations (frameshift, nonsense, and splice) and ZF2 var-
iants are most common in GDMM, GATA2 mutations in sporadic
myeloid malignancies are predominantly missense (mainly in ZF1, but
also throughout the C‐terminus) or in‐frame indels in the C‐terminus,
and premature termination mutations are seen to a lesser extent
(COSMIC v92). This suggests that there may be a fundamental dif-
ference in the role of mutant GATA2 in the leukemogenic process
between germline cases where mutant GATA2 is present in all cells
throughout development including in the BM microenvironment, and
somatic cases where the mutant protein is confined to hematopoietic
cells and is rarely the first mutation acquired (Martignoles
et al., 2018).
There is a need for a more systematic and comprehensive
screening of somatic mutations in these rare cases of GDMM to
better understand the range and frequency of concurrently mutated
genes and why mutations in mutually exclusive genes are not re-
quired or selected for.
F IGURE 1 Germline GATA2 variants. All ascertained germline GATA2 variants are visualized using the ProteinPaint web application (https://
pecan.stjude.cloud/home) (Zhou et al., 2016). Variants (displayed as protein changes where possible) are color‐coded according to mutation
effect. The number of probands for each variant is indicated within the circle where the number is greater than one. All variants are annotated to
NM_032638.5
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1.6 | Clinical and diagnostic relevance
Due to the often early onset of G2DS symptoms and the potential
severity of these, it is important to screen for and identify GATA2
germline pathogenic variants to help guide clinical decisions and fa-
cilitate family counseling. Although a family history of myeloid ma-
lignancies or immunodeficiency may help in the decision to screen for
GATA2 variants, it is important to note that GATA2 de novo variants
constitute a significant proportion of cases in some phenotypes such
as in children or young adults with MDS (Wlodarski et al., 2016).
Interestingly, there is even a report of a de novo c.1143+5G>A
variant occurring in monozygotic twins both with typical G2DS
phenotypes (Stray‐Pedersen et al., 2016). Depending on the severity
of the disease at the time of molecular diagnosis, there may be an
urgent need for therapeutic intervention. There are numerous re-
ports of the requirement for early HSCT for G2DS patients with
immunodeficiency or myeloid malignancies (Cuellar‐Rodriguez et al.,
2011; McReynolds et al., 2018).
Considering the variable phenotypes in G2DS, family cascade
testing of an inherited pathogenic variant may identify carriers that
are asymptomatic or have a subclinical presentation within the
spectrum of the disorder. Since the first report of GATA2 as a pre-
disposition gene for myeloid malignancies in 2010 (Scott et al., 2010),
screening for germline variants in relatives has been increasingly
implemented to select for HSCT donors that do not carry the variant
to avoid donor‐derived MDS/AML (Galera et al., 2018) or for in-
dividuals that may need surveillance for malignancy or im-
munodeficiency, and this is becoming routine in many clinics
(DiNardo et al., 2016; University of Chicago Hematopoietic Malig-
nancies Cancer Risk Team, 2016). In cases of myeloid malignancy, it is
becoming widely recognized that different somatic mutations can
have different prognostic values. In children and adolescents with
F IGURE 2 Prevalence of GATA2 variant type and associated G2DS phenotypes. (a) Number and type of unique GATA2 variants. (b) Total
number and variant type of GATA2 individuals. (c) Percentage of individuals with each GATA2 variant type associated with each phenotype. (d)
Percentage of individuals with each GATA2 variant type with associated hematological malignancies. Loss‐of‐function (LOF), frameshift (FS),
nonsense (NS), missense (MS), splice site (SPL), large deletion (DEL), small insertion/deletion (INDEL), regulatory (REG), all variants combined
(total). Overall phenotypes: L, lymphedema; M/A, MDS and/or AML; ID, immunodeficiency; malignancy types: myelodysplastic syndrome (MDS),
acute myeloid leukemia (AML), myeloproliferative neoplasm (MPN). B‐ or T‐cell acute lymphoblastic leukemia (ALL), acute leukemia (AL)
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MDS and monosomy 7, germline GATA2 variants do not confer
poorer outcomes (Wlodarski et al., 2016).
Currently, HSCT is the most common treatment for the blood‐
related phenotypes in G2DS (immunodeficiency and myeloid malig-
nancy). Considering the high risk of developing these conditions,
providing early genetic diagnosis to patients and/or their relatives
before onset could allow more time to identify optimal HSCT donors,
and lead to improved outcomes of transplantations.
Although GATA2 variants can predispose to G2DS symptoms,
other influences may be important in expression of these variants
such as epigenetics. One report provided evidence of monoallelic
expression of the p.Thr354Met allele in symptomatic patients while
asymptomatic individuals display equal expression from both
p.Thr354Met and wildtype alleles (Al Seraihi et al., 2018). Such si-
lencing of the wildtype allele may be selected to further reduce
GATA2 activity to even more “favorably” low levels for aberrant cell
expansion or survival under certain conditions. Whether the stimulus
for such epigenetic changes is physiological or environmentally dri-
ven is unknown.
The ability to correct GATA2 pathogenic variants using gene
therapeutic or editing approaches, particularly in the hematopoietic
system, is an attractive idea. A recent paper reported evidence of a
spontaneous GATA2 somatic genetic rescue event in the hemato-
poietic system of an elderly asymptomatic individual, opening up the
exciting possibility of therapeutic strategies to facilitate and expedite
correction of pathogenic variants to enable hematopoietic recovery
or normalization (Catto et al., 2020).
1.7 | In vivo models to dissect the functional role
of GATA2 in hematopoietic and nonhematopoietic
tissues
Before the discovery of GATA2 as a disease gene in humans, the first
Gata2 knockout (KO‐Gata2−/−) mice generated showed embryonic
lethality at 10.5 days post coitum due to lack of definitive hemato-
poiesis and severe anemia (Tsai et al., 1994). Further characterization
on mouse embryonic stem cells showed that GATA2 is required for
proliferation of early hematopoietic stem cells (HSC) and that loss of
GATA2 expression interrupts normal embryonic development (Tsai &
Orkin, 1997; Tsai et al., 1994). Heterozygous Gata2+/− mice survive
until adulthood and are normal and fertile despite reduced expression
(~50%) of Gata2 compared to wild‐type mice (Tsai & Orkin, 1997;
Tsai et al., 1994). In the setting of stress hematopoiesis, BM from
Gata2+/− mice exhibited a reduction in the abundance and func-
tionality of immunophenotypically defined HSC (Guo et al., 2013;
Rodrigues et al., 2005) displaying a phenotype resembling patients
with G2DS immunodeficiency (Brown et al., 2020). Gata2 hap-
loinsufficiency also reduced granulocyte‐macrophage progenitor
(GMP) cell function while leaving other myeloid committed progeni-
tors intact (Rodrigues et al., 2008). Together, these observations
show that GATA2 plays a stage‐specific differentiation role not only
in the HSC but also the GMP compartment and that germline GATA2
LOF variants in humans may act similarly to predispose to distinct
diseases such as MDS/AML, immunodeficiency, and lymphedema
(Brown et al., 2020; Pasquet et al., 2013).
Interestingly, a study on the effect of hypomorphic Gata2
variants in mice showed that reduction of GATA2 expression to
~20% induced development of chronic myelomonocytic leukemia‐
like leukemia (Harada et al., 2019). Furthermore, animal models
have shown the importance of the mouse Gata2 −77 kb upstream
and +9.5 kb intronic enhancers in hematopoietic cell production
and differentiation in embryonic, fetal, and adult hematopoiesis
(reviewed in Bresnick et al., 2020; Johnson et al., 2020; Soukup &
Bresnick, 2020). Germline variants in the +9.5 kb enhancer in hu-
mans predispose to myeloid malignancies, aplastic anemia, im-
munodeficiency, and lymphedema (Hsu et al., 2013; Johnson
et al., 2012).
Tissue‐specific conditional KO models of Gata2 have been used
to interrogate its roles in various tissues during later stages of de-
velopment. For instance, conditional KO of Gata2 under control of
VECre (i.e., VE‐Cadherin‐Cre: Gata2 deletion in vascular endothelial
cadherin‐expressing endothelial cells before HSC formation) and
Vav‐Cre (Gata2 deletion in hematopoietic cells after HSC generation)
showed that complete deletion of Gata2 in these tissues was em-
bryonic lethal due to defects in endothelial to hematopoietic transi-
tion during HSC formation and HSC survival (de Pater et al., 2013).
The VECre mediated Gata2 loss resulted in death from anemia, he-
morrhage, and edema due to lymphatic dysfunction (Lim et al., 2012).
In addition, conditional loss of Gata2 in lymphatic endothelial cells
during development results in dermal lymphatic vessel mispatterning
and loss of lymphovenous valves (Frye et al., 2018; Kazenwadel et al.,
2015). These elegant mouse studies have established the crucial role
of GATA2 not only in hematopoiesis but lymphatic development.
Another interesting finding from tissue‐specific knockdown of Gata2
was using an MSC‐specific Prx1 gene promoter in mice (Hasegawa
et al., 2017). Their results suggested that GATA2 regulates cell ad-
hesion and chemotaxis in BM to maintain the BM microenvironment,
and that loss of GATA2 in mesenchymal stromal cells (MSC) may
contribute to aberrant HSC colony formation (Hasegawa et al., 2017).
This finding suggested that GATA2‐associated BM disorders may not
solely result from HSC intrinsic processes, but also the BM niche. This
is correlated with evidence that GATA2 expression is decreased in
BM MSC from patients with aplastic anemia (Xu et al., 2009). In a
different context, rescue of hematopoietic deficiency of GATA2 using
a Gata2 yeast artificial chromosome transgene in mice led to the
discovery of a contribution to urogenital development (Zhou et al.,
1998). These mice suffered from megaureter and hydronephrosis
caused by ureters that ended blindly or were aberrantly connected to
the seminal vesicle or vas deferens and resulted in perinatal lethality.
Interestingly, these findings are consistent with urogenital abnorm-
alities being seen in 5%–12% of G2DS patients (Donadieu et al.,
2018; Wlodarski et al., 2016).
Overall, mouse models have contributed greatly to our under-
standing of the role(s) of GATA2 in the genesis and function of he-
matopoietic and nonhematopoietic tissues. To date, there are no
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knockin mouse models that mimic any of the commonly seen human
missense variants. Furthermore, few have faithfully modeled the in-
itiation and progression of G2DS phenotypes as seen in human dis-
ease (e.g., MDS or AML), possibly due to the short murine lifespan
and the different range of challenges and stressors experienced
during a human lifetime.
2 | CONCLUSION
In just one decade, the impact of germline GATA2 pathogenic variants
has been noted around the world, and clinical practice has changed to
help patients and their families. This collation of published GATA2
variants is a powerful resource for helping health professionals in
ACMG/AMP classification of identified variants and subsequent
clinical management. A better understanding of the types of GATA2
variants and their impacts on the cellular processes and environ-
mental stressors leading to G2DS phenotypes will enable better
surveillance measures, treatments, and ultimately strategies to pre-
vent disease onset.
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